Biosimilar Action Plan Report Card

In July of 2018, the U.S. Food and Drug Administration (FDA) released the Biosimilars Action Plan (BAP). The plan detailed key actions to promote innovation and competition among biologics and enhance the development of biosimilars, potentially lowering costs for patients and payors. At the one year mark, the agency has made significant progress with the BAP, but more can be done to ensure biosimilars are approved as efficiently as possible.

View the report card below to see the status of initiatives laid out in the plan.

About AAM

AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 22 percent of total drug spending.

About the Biosimilars Council

The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.